Related scientific articles (all)

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.

Authors : Sculier C, Bentea G, Ruelle L, Grigoriu B, Coureau M, Gorham J, Sideris S, Holbrechts S, Lafitte JJ, Meert AP, Durieux V, Berghmans T, Sculier JP
Year : 2017
Journal : Lung Cancer
Volume : 111
Pages : 164-175

Breast cancer treatment-induced cardiotoxicity.

Authors : Martel S, Maurer C, Lambertini M, Pondé N, de Azambuja E
Year : 2017
Journal : Expert Opin Drug Saf
Volume : 16(9)
Pages : 1021-1038

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Authors : Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Year : 2017
Journal : J Clin Oncol
Volume : 35
Pages : 1421-1429

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Authors : Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, OShaughnessy J
Year : 2017
Journal : Breast Cancer Res Treat
Volume : 166(1)
Pages : 327-328

The footprint of the ageing stroma in older patients with breast cancer.

Authors : Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Floris G, Van den Eynde K, Bareche Y, Schöffski P, Smeets A, Neven P, Lambrechts D, Sotiriou C, Wildiers H
Year : 2017
Journal : Breast Cancer Res
Volume : 19
Pages : 78

Management of stage III non-small cell lung cancer.

Authors : Tabchi S, Kassouf E, Rassy EE, Kourie HR, Martin J, Campeau MP, Tehfe M, Blais N
Year : 2017
Journal : Semin Oncol
Volume : 44
Pages : 163-177

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Authors : Gingras I, Holmes E, de Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart-Gebhart M, Azim HA Jr
Year : 2017
Journal : J Natl Cancer Inst
Volume : 109

Management of supratentorial recurrent low-grade glioma: A multidisciplinary experience in 35 adult patients.

Authors : Spitaels J, Devriendt D, Sadeghi N, Luce S, De Witte O, Goldman S, Mélot C, Lefranc F
Year : 2017
Journal : Oncol Lett
Volume : 14
Pages : 2789-2795

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

Authors : Kourie HR, Awada G, Awada A
Year : 2017
Journal : Immunotherapy
Volume : 9
Pages : 647-657

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors : Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G
Year : 2017
Journal : Oncotarget
Volume : 8(2)
Pages : 2320-2328

Targeting immune checkpoints in breast cancer: an update of early results.

Authors : Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L
Year : 2017
Journal : ESMO Open
Volume : 2
Pages : e000255

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Authors : Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS
Year : 2017
Journal : Breast Cancer Res Treat
Volume : 163(3)
Pages : 535-544

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors : Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 1700-1712

How to emerge from the conservatism in clinical research methodology?

Authors : Kotecki N, Penel N, Awada A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29(5)
Pages : 400-404

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.

Authors : Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Year : 2017
Journal : Clin Cancer Res
Volume : 23(15)
Pages : 4323-4334

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Authors : Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, Van Poppel H, Wait S, Naredi P
Year : 2017
Journal : Eur J Cancer
Volume : 82
Pages : 193-202

Predictors of physicians' communication performance in a decision-making encounter with a simulated advanced-stage cancer patient: A longitudinal study.

Authors : Libert Y, Canivet D, Ménard C, Van Achte L, Farvacques C, Merckaert I, Liénard A, Klastersky J, Reynaert C, Slachmuylder JL, Durieux JF, Delvaux N, Razavi D
Year : 2017
Journal : Patient Educ Couns
Volume : 100(9)
Pages : 1672-9

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study

Authors : Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenar E, Degardin M, Pateras IS, Langendijk JA, Van Herpen C, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB
Year : 2017
Journal : Ann Oncol
Volume : 28(9)
Pages : 2213-2218

Reply to: Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks or Modern Cancer Therapies.

Authors : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Year : 2017
Journal : Ann Oncol
Volume : 29(3):
Pages : 774-775

New agents for endocrine resistance in breast cancer.

Authors : Maurer C, Martel S, Zardavas D, Ignatiadis M
Year : 2017
Journal : Breast
Volume : 34
Pages : 1-11